Radiopaque intraluminal stents comprising cobalt-based alloys containing one or more platinum group metals, refractory metals, or combinations thereof

Patent metadata

Field	Value
Publication number	US-9566147-B2
Application number	US-201313830404-A
Country	US
Kind code	B2
Filing date	Mar 14, 2013
Priority date	Nov 17, 2010
Publication date	Feb 14, 2017
Grant date	Feb 14, 2017

Abstract

Embodiments are directed to radiopaque implantable structures (e.g., stents) formed of cobalt-based alloys that comprise cobalt, chromium and one or more platinum group metals, refractory metals, precious metals, or combinations thereof. Platinum group metals include platinum, palladium, ruthenium, rhodium, osmium, and iridium. Refractory metals include zirconium, niobium, rhodium, molybdenum, hafnium, tantalum, tungsten, rhenium, and precious metals include silver and gold. In one embodiment, the one or more included platinum group or refractory metals substitute at least partially for nickel, such that the alloy exhibits reduced nickel content, or is substantially nickel free. The stents exhibit improved radiopacity as compared to similar alloys including greater amounts of nickel.

First claim

The invention claimed is:

1. A radiopaque stent, comprising:
a cylindrical main body comprising a cobalt-based alloy including cobalt, chromium, platinum, palladium, and an austenitic stabilizer for cobalt including a combination of manganese and optionally nickel, the cobalt-based alloy including less than 5 weight percent nickel and comprising no more than about 20 percent by weight iron;
wherein the cobalt-based alloy has a relative radiopacity greater than 4.5 barnes/cm 3 , and wherein the radiopaque stent has at least 20% elongation to achieve adequate stent expansion;
wherein an entirety of the stent is formed from the cobalt-based alloy.

2. A radiopaque stent, comprising:
a cylindrical main body comprising a cobalt-based alloy including cobalt, chromium, manganese, and at least one of platinum or palladium;
wherein a collective amount of platinum and/or palladium in addition to any included amount of one or more other platinum group metals, refractory metals, or precious metals selected from the group consisting of rhodium, iridium, osmium, ruthenium, zirconium, niobium, hafnium, tantalum, tungsten, rhenium, silver, and gold, is at least 10% by weight of the cobalt-based alloy, the cobalt-based alloy including no more than 1% nickel by weight, and comprising no more than about 20% by weight iron;
wherein the cobalt-based alloy has a relative radiopacity greater than 4.5 barnes/cm 3 , and wherein the radiopaque stent has at least 20% elongation to achieve adequate stent expansion;
wherein an entirety of the stent is formed from the cobalt-based alloy.

3. The radiopaque stent of claim 2 , wherein the cobalt-based alloy further comprises molybdenum.

4. The radiopaque stent of claim 2 , wherein the cobalt-based alloy is entirely free of nickel.

5. The radiopaque stent of claim 2 , wherein the cobalt-based alloy comprises no more than about 16 percent by weight iron.

6. The radiopaque stent of claim 2 , wherein the cobalt-based alloy comprises no more than about 4 percent by weight iron.

7. The radiopaque stent of claim 2 , wherein the cobalt-based alloy comprises from about 18 weight percent to about 50 weight percent cobalt, from about 10 weight percent to about 25 weight percent chromium, and the collective amount of platinum, palladium, rhodium, iridium, osmium, ruthenium, zirconium, niobium, hafnium, tantalum, tungsten, rhenium, silver, and gold is from about 10 weight percent to about 65 weight percent.

8. The radiopaque stent of claim 7 , wherein the collective amount of platinum, palladium, rhodium, iridium, osmium, ruthenium, zirconium, niobium, hafnium, tantalum, tungsten, rhenium, silver, and gold is from about 10 weight percent to about 35 weight percent.

9. The radiopaque stent of claim 7 , wherein the cobalt-based alloy comprises from about 22 weight percent to about 40 weight percent cobalt.

10. The radiopaque stent of claim 7 , wherein the cobalt-based alloy comprises from about 40 weight percent to about 50 weight percent cobalt.

11. The radiopaque stent of claim 2 , wherein the cobalt-based alloy comprises from 31 weight percent to 51 weight percent cobalt, from 15 weight percent to 20 weight percent chromium, from 1 weight percent to 25 weight percent manganese, and wherein a combined weight percent of platinum and palladium is; from 8 weight percent to 30 weight percent of the cobalt-based alloy.

12. The radiopaque stent of claim 11 , wherein the cobalt-based alloy comprises from 1 weight percent to 17 weight percent of manganese.

13. The radiopaque stent of claim 11 , wherein the cobalt-based alloy comprises from 1 weight percent to 10 weight percent of manganese.

14. The radiopaque stent of claim 11 , wherein the cobalt-based alloy is formed by providing each constituent metal in solid form, powder form, or both, and melting the constituent metals so as to form the cobalt-based alloy.

15. The radiopaque stent of claim 11 , wherein melting the constituent metals is achieved by arc melting, electro-slag remelting, electron beam melting, induction melting, radiant heat melting, microwave melting, or combinations thereof.

16. The radiopaque stent of claim 11 , wherein the cobalt-based alloy is formed by providing each constituent metal in powder form, mixing the powders together, and compacting and sintering the mixture of constituent metals in powder form so as to form the cobalt-based alloy.

17. The radiopaque stent of claim 2 , wherein the cobalt-based alloy has a relative radiopacity greater than 4.6 barnes/cm 3 .

18. The radiopaque stent of claim 2 , wherein the cobalt-based alloy further comprises from about 10 weight percent to about 15 weight percent tungsten.

19. A radiopaque stent, comprising:
a cylindrical main body comprising a cobalt-based alloy including cobalt, chromium, an austenitic stabilizer for cobalt including a combination of manganese and optionally nickel, and one or more platinum group metals or precious metals selected from the group consisting of platinum, palladium, rhodium, iridium, osmium, ruthenium, silver and gold, the cobalt-based alloy including less than 5 weight percent nickel and comprising no more than about 20 percent by weight iron;
wherein the cobalt-based alloy has a relative radiopacity greater than 4.5 barnes/cm 3 , and wherein the radiopaque stent has at least 20% elongation to achieve adequate stent expansion;
wherein an entirety of the stent is formed from the cobalt-based alloy.

20. The radiopaque stent of claim 19 , wherein the cobalt-based alloy comprises no more than about 4 percent by weight iron.

21. The radiopaque stent of claim 19 , wherein the cobalt-based alloy comprises from 31 weight percent to 51 weight percent cobalt, from 15 weight percent to 20 weight percent chromium, from 8 weight percent to 30 weight percent of one or more platinum group metals selected from the group consisting of platinum and palladium, and from 1 weight percent to 10 weight percent manganese, the combined weight percent of manganese and nickel being from 3 weight percent to 10 weight percent.

22. The radiopaque stent of claim 19 , wherein the one or more platinum group metals are selected from the group consisting of platinum and palladium.

23. The radiopaque stent of claim 19 , wherein the combined weight percent of manganese and nickel is from 1 weight percent to 25 weight percent.

24. The radiopaque stent of claim 19 , wherein the combined weight percent of manganese and nickel is from 1 weight percent to 17 weight percent.

25. The radiopaque stent of claim 19 , wherein the combined weight percent of manganese and nickel is from 1 weight percent to 10 weight percent.

26. The radiopaque stent of claim 19 , wherein the cobalt-based alloy comprises from 1.3 weight percent to 5 weight percent manganese.

27. The radiopaque stent of claim 19 , wherein the cobalt-based alloy comprises no more than 3.5 weight percent nickel.

28. The radiopaque stent of claim 19 , wherein the cobalt-based alloy has a relative radiopacity from 4.6 barnes/cm 3 to 6.5 barnes/cm 3 .

Assignees

• Abbott Cardiovascular Systems Inc

Inventors

• Kramer-Brown Pamela A
• Calvert Kayla L
• Simpson John A
• Pacetti Stephen D
• Leach Austin M

Classifications

• C22C27/00

  Alloys based on rhenium or a refractory metal not mentioned in groups C22C14/00 or C22C16/00 · CPC title

• A61F2250/0098

  radio-opaque, e.g. radio-opaque markers · CPC title

• A61F2/06 Primary

  Blood vessels · CPC title

• C22C27/06

  Alloys based on chromium · CPC title

• A61L31/18

  Materials at least partially X-ray or laser opaque · CPC title